TREATMENT OF INFLAMMATORY BOWEL DISEASE AND PREGNANCY: a review of the literature

Lucianna Motta CORREIA, Danielle Queiroz BONILHA, Juliana Dantas RAMOS, Orlando AMBROGINI and Sender Jankiel MISZPUTEN

ABSTRACT – Context - The inflammatory bowel disease is diagnosed frequently among woman of childbearing capacity. The management must be carefully because there are potential risks for the mother and fetus. Results and conclusions - We review literature about the management of inflammatory bowel disease in pregnancy. Some studies are needed to ensure the best approach to inflammatory bowel disease in pregnant women.

INTRODUCTION

Inflammatory bowel disease (IBD) frequently affects women in childbearing age. During pregnancy, clinical exacerbations not treated adequately may have serious consequences to the pregnant woman and to the fetus. The teratogenicity of the drugs used in treatment of IBD is rarely described but the unknowledgment about this by physicians and patients leads to inadvertent discontinuation of treatment. However, the controlling the activity of the disease is the main determinant of the good prognosis of pregnancy.

Clinical manifestations during the pregnancy

The manifestations of IBD during the pregnancy are the same of that in non-pregnancy. The majority of pregnancies in patients with IBD, although classified as high risk, courses without several complications. Reports of clinical exacerbation, especially in the first trimester, occurs in up to one third of pregnant women with IBD. Bortoli et al. found recurrence rates of disease in 17.3% of women that were in remission, being more frequent in patients with idiopathic ulcerative rectocolitis (IUR) compared to those with Crohn’s disease (CD), but without statistical difference (P = 0.38). Nineteen percent of births occurred during clinical exacerbations and 8.7% during remission, all carriers of IUR. Riss et al. analyzing cohort study in 508 women diagnosed with IBD before or after pregnancy, have not observed differences in the pattern of disease or need for surgery for their adequate control, but identified reduction in the number of episodes of clinical exacerbation, after pregnancy. However, the risk of clinical exacerbations is no greater than any other period in life.

Furthermore, the adequate control of disease activity seems to be the main prognostic factor in pregnancy. Disease activity is associated with increased number of spontaneous abortions, premature deliveries, babies born with low weight and/or small for gestational age and increased demand for surgical deliveries. However, the DII does not increase the risk of maternal complications such as hypertension or proteinuria.

Regarding IUR, about 70%-80% of patients remain in remission during pregnancy and rates of relapse are similar to non pregnant. Up to 7% present the first episode of colitis during pregnancy or puerperal period. Carriers of ileum-anal anastomosis tolerate pregnancy better and exacerbations have more light and transient, resolving completely up in the post-partum period. The rates of cesarean sections are higher in carriers of the disease, although IUR by itself represents no formal indication for this route of delivery.

The behavior of CD pattern is similar to the IUR during pregnancy. If the design is done in time to clinical remission, this is kept up to 70% of patients. Relapses occur most often during the first trimester and puerperium. Nor is there consensus on the route of delivery indicated, should be considered obstetric indications.

Women with IBD have a risk twice higher than the general population to have premature births.
or children considered of low birth weight and greater likelihood of surgical deliveries, which seems more related to activity of disease than the side effects of medications. Otherwise, the pregnancy can be quite normal in this group of patients. The best obstetric prognostic factor is the control of disease.

**Diagnosis during the pregnancy**

Peculiarities in the diagnosis in this situation should be remembered. The evidence of inflammatory activity are commonly altered in pregnancy without necessarily reflecting activity of disease, but the levels of C-reactive protein (CRP) tends to be elevated in this period and may be useful as markers. Because of hemodilution, the hemoglobin and albumin are little reliable parameters for evaluation of activity and it decreases with the progression of pregnancy. Iron deficiency is common in this situation and should not be used as a marker of blood loss. Regarding the endoscopic examinations, the retotisigmoidoscopy is relatively safe and may help in the diagnosis of active colitis. In addition, the safety of colonoscopy is still questionable during pregnancy.

Radiologic investigation should be avoided, unless perforation, toxic megacolon or obstruction are suspected. Ultrasound and magnetic resonance are safe for use in this situation.

Furthermore, pregnancy does not appear to influence the course of the disease or the need for surgical treatment, but appears to be associated with reduced number of relapses over the next years.

**Treatment of IBD during pregnancy and breastfeeding**

**Nutritional support**

Acid folic supplementation is recommended for all pregnant woman, especially in use of sulfasalazine or in disease activity. The recommended doses are 5 mg/day. In pregnant women in use of steroids, the supplement of vitamin D should be administered. Precoce nutritional supplementation is recommended to pregnant women with no weight gain during disease activity. Total parenteral nutrition should be initiied in very sick patients.

**Drug therapy**

The drug in this context is perhaps the biggest source of doubt regarding the clinical management of IBD in pregnancy. We describe the medical treatment more frequent used in this condition.

a) **Aminosalicilates**

The use of aminosalicilates has been relatively safe, included during breastfeeding. The sulfasalazine (SSZ), considered as Class B by the Food and Drugs Administration (FDA), crosses the placental barrier and reaches the fetus in concentrations similar to maternal, not related to increased morbidity or fetal abortions. However, some previous reports have described potential teratogenicity for this drug. There are some studies that describe neonatal jaundice with SZA. The replacement of folic acid is recommended because of the antagonistic effects of SSZ, interacting with the cell membrane transporters.

The mesalazine (MZA) in conventional doses is safe during pregnancy and in higher doses (above 3 g/d) at risk of developing interstitial nephritis in newborn but without teratogenicity. It is also considered Class B drug for use during the pregnancy. It is excreted in breast milk, without significant risk to newborn.

b) **Corticosteroids**

Steroids seem to be safe during pregnancy, with no convincing evidence of teratogenicity. They are indicated in moderately to severe cases. Findings of low birth weight and newborns small for gestational age during the use of prednisolone during pregnancy have not been confirmed in more recent studies. It is classified as Class C for use during pregnancy. The prednisolone should be the choice because of the fetal exposure is lower when compared with betamethasone and dexamethasone.

In a metanalysis, prednisone increases to 5-4-fold the risk of oral cleft, but without major complications in therapeutic doses. However, oral budesonide seems to be safe, in doses 6 to 9 mg/d, without reports of maternal adrenal suppression, glucose intolerance, ocular side effects, hypertension or fetal conegenital abnormalities. There seems to be no significant placental transfer of topical corticosteroids, but there is a small number of researches. Its use seems to be safe in the first trimester and the benefits outweighed the risks of activity disease uncontrolled. The administration rote, oral, parenteral or topical, depends to severity of disease activity and tolerability of patient.

c) **Immunosuppressive drugs**

There is no evidence so far of adverse effects of azathioprine (AZA) when the adequate doses. Despite apparent certainty as to the use is not recommended the initiation of therapy during pregnancy for its potential myelotoxicity, but for those who already are in therapy to maintain the suspension is not necessary. The 6-mercaptopurine (6 MP) increases the risk of miscarriage and premature births in humans and its use is inadvisable during gestation. Drugs are considered by the FDA for use class D during pregnancy. The 6-MP excretion in the breast milk occurs within the first 4 hours after intake, with low concentration to the newborn. The use during breastfeeding should be recommended.

The use of cyclosporine (class C) should be considered only in severe cases not responsive to steroids, to avoided emergency colectomy that presents elevated mortality. Its use has been related to prematurity and fetal growth retardation, in addition to the potential risk of renal and hepatic toxicity in pregnancy use. In doses that aimed for blood levels 200 ng/mL seems to be safe in inducing remission in patients with several activity of IUR.

Methotrexate (MTX) is an alternative to AZA in patients with steroid refractoriness. Is contraindicated in pregnancy.
for its mutagenic and teratogenic effects, because interferes in acid folic metabolism and purine synthetase. It is being associated with cranio-facial malformations, central nervous system abnormalities, including anencephaly, and defects in members. If a pregnancy occurs during its use, the drug should be suspended immediately and pregnant women should receive high doses of folic acid.

Tacrolimus is an immunosuppressant with action similar to cyclosporine. It is contraindicated to breastfeeding and is associated to perinatal hyperkalemia and prematurity.

Thalidomide is an option to refractory CD but is an drug class X for FDA and contraindicated to pregnant women and breastfeeding.

d) Antibiotics

The use of antibiotics may be necessary at times during the treatment of patients with IBD, especially Crohn’s disease. The drug metronidazole is teratogenic in animals, but does not appear to be associated with deleterious effects on humans. However, there are few data available with respect to their effects at higher doses and for longer periods, as is usually necessary in patients with IBD. Potential toxicity is related with long-term use while breastfeeding.

Ciprofloxacin and other quinolones have been used in pregnant women without evidence of congenital or musculoskeletal abnormalities in children and should be avoided its use in the first trimester. However, more studies are needed to confirm. Its use seems to be safe in breastfeeding. Tetracycline and sulfonamides are contraindicated in pregnancy. Amoxicillin with or no clavulanic acid is compatible with breastfeeding and does not increase the risks for congenital anomalies.

e) Biological therapy

The biological therapy with infliximab has changed the course of IBD considered refractory. So far, no evidence of adverse effects (maternal toxicity, embryotoxicity, teratogenicity) with its use during pregnancy in isolated models animals. Report described complications such as premature birth and neonatal death in intracerebral hemorrhage and/or the lung in humans.

Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha (TNF-α), considered effective for both induction and for maintenance of clinical remission of the CD. The initial dose, administered intravenously, is 5 mg/kg at week 0, 2 and 6 for induction of response and maintained this dose every 8 weeks for maintenance of remission. It is classified as FDA class B drugs for use during pregnancy. There are few isolated reports of associated malformations, but most studies have been favorable to its use in period.

What is known, however, is that efforts should be made to control the IBG during pregnancy, as activities with greater intensity may put at risk both the mother and the fetus. The outcomes in pregnant women seems not different that in the general population.

Serum levels of infliximab can be found in newborns of mothers who used this medication during pregnancy. What can explain this fact is the transplacental transfer of maternal antibodies in the first quarter, as it is an antibody of Class IgG. In some reports found, this transfer does not seem to be harmful to the fetus (Table 1) and, similar to other maternal antibodies, infliximab has a half-life prolonged in the newly born. There is no evidence of excretion this drug in the mother’s milk.

Adalimumab is classified as class B drugs for use during pregnancy. In a case report with the use of adalimumab found no morbidity related to this medication. There is no date on its safety on breastfeeding until the moment.

Aussalah at al. report a case of a pregnant woman that was successfully treated with certulizumab but the safety of certulizumab is unknown.

CONCLUSIONS

Fear of congenital malformations and/or severe side effects or birth defects related to medications is the main responsible for the difficulty in obtaining effective treatment during pregnancy. However, the prognostic factor of major importance in pregnant women suffering from inflammatory bowel disease is adequate control of disease activity in this period. Clarification of the patients and physicians to this fact may reduce complications.

### TABLE 1. Case reports

<table>
<thead>
<tr>
<th>Reference</th>
<th>n</th>
<th>Disease</th>
<th>Drug</th>
<th>Infusion</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roux et al.</td>
<td>3</td>
<td>RA</td>
<td>Etanercept, adalimumab</td>
<td>Maintenance</td>
<td>Prematurity, neonatal jaundice, congenital adrenal hyperplasia</td>
</tr>
<tr>
<td>Vasiliasonas et al.</td>
<td>1</td>
<td>Crohn</td>
<td>Infliximab (10 mg/kg)</td>
<td>Maintenance</td>
<td>Normal birth without comorbidities</td>
</tr>
<tr>
<td>Mahadevan et al.</td>
<td>10</td>
<td>Crohn</td>
<td>Infliximab</td>
<td>2 induction</td>
<td>Premature birth and low birth weight</td>
</tr>
<tr>
<td>Katz et al.</td>
<td>96</td>
<td>Crohn, RA</td>
<td>Infliximab</td>
<td>8 maintenance</td>
<td>Spontaneous abortions in 15% and therapeutic abortions in 19% Results did not differ from those of other patients with Crohn’s disease, who did not receive infliximab</td>
</tr>
<tr>
<td>Chakravarthy et al.</td>
<td>2</td>
<td>RA</td>
<td>Infliximab</td>
<td>Maintenance</td>
<td>Without findings of teratogenicity or maternal morbidities</td>
</tr>
<tr>
<td>Palmer et al.</td>
<td>1</td>
<td>RCU1</td>
<td>Infliximab</td>
<td>Induction</td>
<td>Fetal obst</td>
</tr>
</tbody>
</table>

RESUMO – Contexto - A doença inflamatória intestinal acomete mulheres em idade fértil com relativa frequência. A conduta exige maior atenção durante esta condição clínica em virtude dos riscos potenciais de complicações materno-fetais. Resultados e conclusões - Esta é uma revisão sobre as manifestações clínicas das doenças inflamatórias intestinais durante a gravidez e seu tratamento durante este período. Ainda são necessários estudos sobre o tema para melhor abordagem das doenças inflamatórias intestinais em gestantes.


REFERENCES


Received 22/4/2009.
Accepted 3/9/2009.